The FDA record for K261740 lists Robotrak Technologies Co., Ltd. as applicant for the Mona IV Adaptive Optics Scanning Laser Ophthalmoscope, product code MYC, under regulation 886.1570 for a scanning laser ophthalmoscope in device class 2. The filing was received May 27, 2026, and decided October 27, 2026, with decision code SESE and the description “Substantially Equivalent.” The record identifies a Traditional clearance type, the Ophthalmic advisory committee and a Summary statement. The filing address is in Jiangning District, Nanjing, China; that address is a filing detail, not a verified headquarters. [1]
The Mona IV clearance and its documented scope
K261740 covers the Mona IV Adaptive Optics Scanning Laser Ophthalmoscope, a class 2 ophthalmic device under product code MYC. The FDA entry records a Traditional 510(k), no third-party review, and a decision of substantially equivalent dated October 27, 2026. The record does not state indications for use, so the cleared labeling scope is unknown beyond the device name and classification. [1]
Robotrak’s own announcement describes the Mona IV as an adaptive optics scanning laser ophthalmoscope and states that the clearance applies to the device and indications for use specified in the FDA decision. The announcement also calls it the first FDA-cleared adaptive optics retinal imaging system; that characterization is the manufacturer’s, not an FDA statement in the record. [2]
Product features as published by the manufacturer
The Mona IV product page lists a 0.7 μm digital resolution figure, more than 10 retinal microstructures at cellular resolution, real-time eye tracking and automatic montage. It lists photoreceptor quantification as available in a research version only. These are manufacturer-published specifications and feature descriptions, rather than independently verified performance results. [4]
Robotrak’s homepage lists the Mona IV alongside the Charis adaptive optics multimodal ophthalmic imaging system for animals, the Saris multimodal ophthalmic imaging system for animals and the Aglaia 577 intelligent navigated laser system, plus several contact lens lines. The Chinese-language site adds the Archer 577 and Archer 577 Pro lasers and the Nuage Vi autorefractor. Listing a product does not establish its regulatory status in any market. [3][6]
Company background and stated capabilities
Robotrak’s about page states that the company was founded in 2017 and is headquartered in Nanjing, China, and describes work across retinal imaging, precision therapy, myopia management and vision correction. It attributes its imaging work to optics, photonics, intelligent algorithms and materials science. The page also lists figures for facility size, team members, financing rounds, medical device certificates, product pipelines and intellectual property; these are company statements without independent verification in the sources. [5]
The Chinese-language homepage describes the company as founded in 2017 in Nanjing and names adaptive optics, optical design and precision manufacturing, eye tracking, precise laser positioning, artificial intelligence, image algorithms and materials among its technologies. It refers to more than one hundred authorized patents at home and abroad. These claims originate with the manufacturer. [6]
Institutional placement and filing snapshot
A Robotrak news item dated October 23, 2026, states that a Mona IV was installed at the Cole Eye Institute, part of Cleveland Clinic in the United States, and frames the placement as an opportunity to bring adaptive optics into ophthalmic research. The item is the manufacturer’s account; no independent confirmation appears in the sources. [7]
The linked FDA collection contains one 510(k) record, K261740, with one SESE decision, and the record sample contains that same single entry. These counts describe the filings retrieved as of November 20, 2026, not total company sales, total portfolio or safety performance. No recall records appear in the collection. [1]

